Skip to main content
SpringerLink
Log in

Innovation auf dem Gebiet der Kontrazeption

Erstes orales Kontrazeptivum mit Estetrol zugelassen

  • Fortbildung
  • Innovation in der Kontrazeption
  • Published:
gynäkologie + geburtshilfe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Böttiger LE et al. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;1:1097-101

  2. Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 2010;11:1147-57

  3. Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531-9

  4. Zucconi G et al. Isolation of 15-alpha-hydroxy-oestriol from pregnancy urine and from the urine of newborn infants. Acta Endocrinol (Copenh) 1967;56:413-23

  5. Coelingh Bennink F et al. Maternal and fetal estetrol levels during pregnancy. Climacteric 2008;11 Suppl 1:69-72

  6. Coelingh Bennink HJ et al. Estetrol review: profile and potential clinical applications. Climacteric 2008;11 Suppl 1:47-58

  7. Visser M et al. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric 2008;11 Suppl 1:64-8

  8. Arnal JF et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev 2017;97:1045-87

  9. Gérard C et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget 2015;6:17621-36

  10. Coelingh Bennink HJ et al. Ovulation inhibition by estetrol in an in vivo model. Contraception 2008;77:186-90

  11. Klipping C et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25

  12. Susan S Jick, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorestrel: case-control study using United States claims data. BMJ 2011;342:d2151

  13. Creini MD et al. Estetrol-Drospirenone Combination Oral Contraceptive: North American Phase 3 Efficacy and Safety Results. Contraception 2021;S0010-7824(21)00149-9

  14. Clinicaltrial.gov. E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol /Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

  15. Douxfils J et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception 2020;102:396-402

  16. Apter D et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care 2017;22:260-7

Download references

Author information

Authors and Affiliations

  1. Metropol Medical Center, Virnsbergerstraße 79, 90431, Nürnberg, Germany

    Bernd Kleine-Gunk

Authors
  1. Bernd Kleine-Gunk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Kleine-Gunk.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kleine-Gunk, B. Erstes orales Kontrazeptivum mit Estetrol zugelassen. gynäkologie + geburtshilfe 26, 29–31 (2021). https://doi.org/10.1007/s15013-021-4139-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15013-021-4139-5

Search

Navigation